Proficio Capital Partners LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)

Proficio Capital Partners LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 21,212 shares of the biotechnology company's stock, valued at approximately $706,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. bought a new stake in shares of Exelixis in the 4th quarter valued at about $561,000. Oregon Public Employees Retirement Fund boosted its stake in Exelixis by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock valued at $1,937,000 after acquiring an additional 354 shares in the last quarter. Denali Advisors LLC boosted its stake in Exelixis by 49.8% in the fourth quarter. Denali Advisors LLC now owns 12,631 shares of the biotechnology company's stock valued at $421,000 after acquiring an additional 4,200 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in Exelixis by 20.4% in the fourth quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company's stock worth $71,828,000 after purchasing an additional 366,141 shares during the last quarter. Finally, Amalgamated Bank increased its position in shares of Exelixis by 1.7% during the fourth quarter. Amalgamated Bank now owns 142,147 shares of the biotechnology company's stock worth $4,733,000 after purchasing an additional 2,435 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Remove Ads

Insider Transactions at Exelixis

In related news, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares in the company, valued at $13,479,669. This represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 in the last three months. 2.85% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Guggenheim reissued a "buy" rating and issued a $42.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Brookline Capital Management started coverage on Exelixis in a research note on Monday, December 23rd. They set a "buy" rating on the stock. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Exelixis in a report on Thursday, February 13th. Morgan Stanley upgraded shares of Exelixis from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $30.00 to $40.00 in a research note on Monday, January 27th. Finally, JMP Securities restated a "market outperform" rating and set a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $37.24.

Exelixis Trading Up 0.7 %

EXEL traded up $0.27 on Wednesday, reaching $37.20. The stock had a trading volume of 1,786,384 shares, compared to its average volume of 2,084,852. The business's 50-day moving average price is $35.18 and its two-hundred day moving average price is $32.29. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02. The company has a market cap of $10.41 billion, a P/E ratio of 21.00, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.